- 17-OR - ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4 [Board No. 17]
-
3H.L.Heerspink: Consultant; ; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., CSL Behring, Gilead Sciences, Inc., Goldfinch Bio, Inc., Janssen Research & Development, LLC, Mitsubishi Tanabe Pharma Corporation, Mundipharma, Traveere Pharmaceuticals, Research Support; ; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk A/S. N.Sattar: Consultant; ; Afimmune Limited, Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Hanmi Pharm. Co., Ltd., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc., Sanofi, Research Support; ; AstraZeneca, Boehringer Ingelheim International GmbH, Novartis Pharmaceuticals Corporation, Roche Diagnostics. I.Pavo: Employee; ; Eli Lilly and Company, Stock/Shareholder; ; Eli Lilly and Company. A.Haupt: Employee; ; Lilly, Stock/Shareholder; ; Lilly. K.L.Duffin: Employee; ; Eli Lilly and Company, Stock/Shareholder; ; Eli Lilly and Company, Pfizer Inc.. Z.Yang: Employee; ; Eli Lilly and Company. R.Wiese: Employee; ; Eli Lilly and Company. K.R.Tuttle: Advisory Panel; ; Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., Consultant; ; AstraZeneca, Eli Lilly and Company, Research Support; ; Bayer AG, Goldfinch Bio, Inc., Novo Nordisk, Travere. D.Cherney: Other Relationship; ; AbbVie Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Janssen Research & Development, LLC, Lilly, Maze, BMS, CSL-Behring, Merck, Otsuka, Novartis and Novo-Nordisk , Mitsubishi Tanabe Pharma Corporation, Sanofi, Research Support; ; Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca and Novo-Nordisk.TypeTheme AreaCME Hrs.Livestream Session
Enter Note
Go to previous page in this tab
Session